Stockreport

Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF Buy rating on Alumis Inc. (NASDAQ:ALMS) with a price target of $46 after the company presented Phase 3 trial data at the American Academy of Dermatology meeting. Raymo [Read more]